For the year ending 2025-12-31, ARTV had -$13,331K decrease in cash & cash equivalents over the period. -$79,338K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Operating expenses | 89,810 |
| Other income, net | 5,945 |
| Net income (loss) | -83,865 |
| Depreciation and amortization | 2,597 |
| Stock-based compensation | 6,821 |
| Change in fair value of safes (including related party amounts of 0 and 2,911, respectively) | 0 |
| Accretion of discounts and amortization of premiums on investments, net | 1,880 |
| Accounts receivable (including related party amounts of 0 and 569, respectively) | 0 |
| Other receivables (including related party amounts of (61) and 607, respectively) | -79 |
| Prepaid expenses and other current assets | 1,534 |
| Other long-term assets | 191 |
| Accounts payable (including related party amounts of (276) and 76, respectively) | -760 |
| Accrued expenses (including related party amounts of (735) and (1,447), respectively) | 2,003 |
| Operating lease right-of-use asset and lease liabilities, net | -21 |
| Net cash used in operating activities | -76,751 |
| Purchases of property and equipment | 2,587 |
| Purchases of investments | 44,875 |
| Maturities of investments | 110,873 |
| Net cash provided by (used in) investing activities | 63,411 |
| Proceeds from issuance of common stock, net of commissions | 0 |
| Proceeds from exercise of stock options | 138 |
| Proceeds from purchase of espp shares | -233 |
| Payments to taxing authorities related to net-settlement of vested restricted stock units | 230 |
| Payments on finance leases | 132 |
| Cash paid in connection with ipo offering costs | 0 |
| Net cash provided by financing activities | 9 |
| Net decrease in cash, cash equivalents and restricted cash | -13,331 |
| Cash, cash equivalents and restricted cash at beginning of period | 40,493 |
| Cash, cash equivalents and restricted cash at end of period | 27,162 |
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. (ARTV)